Molbio Diagnostics was originally incorporated as ‘Molbio Diagnostics Private Limited’ at Panaji, as a private limited company on October 20, 2000. Thereafter, the company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of the shareholders held on November 22, 2024, and the name of the company was changed to Molbio Diagnostics Limited on January 16, 2025.

The company is an innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. It has developed its ‘Truenat’ platform, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour. Truenat is patented in many countries for the diagnosis of multiple infectious and non-communicable diseases. It offers molecular testing for diseases, including tuberculosis (TB), COVID, Hepatitis B and C, Human immunodeficiency virus (HIV), and Human Papillomavirus (HPV) with multiple assays. 

It also provides devices, enabling radiology, digital pathology and breast health screening, through its subsidiaries, Prognosys and OptraScan and collaboration partner - UE Lifesciences. The company derives its revenues from the sale of its ‘Truenat’ platform, which is designed to work exclusively with its range of ‘Truenat’ test kits that generate recurring revenues. A key feature of its platform is its versatility in diagnostic applications accommodating tests for various infectious and non-communicable diseases. Its platform is designed to connect wirelessly to help healthcare providers manage clinical data and workflow online. This could assist with the transmission of ‘notifiable infections’ to public health authorities to facilitate the tracking of reportable diseases.

Business area of the company 

The company is mainly engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-ray equipment's, single / dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing domain, digital pathology, etc.

Products of the company

• Truenat platform 
• Truenat Test Kits
• Ultraportable X-ray systems
• Mobile X-ray systems
• Fixed X-ray systems
• Ceiling suspended X-ray systems
• High-frequency C-arm systems
• DR retrofit panels

Awards, accreditations and recognition 

• 2019: Recognised as ‘Top 10 In-Vitro Diagnostic Technology Solution Providers - 2019’ by Medtech Outlook magazine.
• 2020: Awarded ‘Product of the Year Award’ for TrueNat by BioSpectrum.
• 2021: Awarded ‘Healthcare Award 2021’ in the category of outstanding research in healthcare: COVID 19- National at the Healthcare Awards conducted by the Economic Times.
• 2022: Awarded ‘Excellence in Innovation in Medical Technology - Company’ award at the 6th Healthcare Excellence Awards conducted by BW Healthcare World.
• 2023: Awarded ‘Good Samaratian Award’ at the 2nd Custodians of Humanity Awards conducted by Integrated Global Healthcare Mission.
• 2023: Received ‘Certificate of Recognition’ by Burgundy Private Hurun India 500.
• 2024: Awarded the ‘Change Maker Awards’ by the Hindu Group.
• 2025: Received ‘Certificate of Recognition’ by ASK Private Wealth and Hurun India in the ASK Private Wealth Hurun India Unicorn and Future Unicorn Report 2025.
• 2025: Awarded the ‘2024 Kochon Prize’ by the Stop TB Partnership for outstanding innovation and excellence towards ending TB.
• 2026: Awarded the ‘Deep-Tech Company of the year’ by VCCircle Edge 2.0 at VCCircle Awards 2026.

History and milestones

• 2000: Incorporation of the company.
• 2000: The company’s R&D arm, Bigtec Private Limited, one of its Subsidiaries commenced its operations.
• 2005: Bigtec directs its focus to chip-based PCR research.
• 2009: Bigtec develops a ‘lab-on-a-chip’ model.
• 2011: Entered into a joint venture agreement dated August 1, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited.
• 2013: Launch of the semi-automatic PCR device ‘Truelab Uno’.
• 2015: Amalgamation of Bigtec Innovations Private Limited with the company.
• 2017: Expert Committee on TB Diagnostics recommended the use of the ‘TrueNat MTB’ and ‘TrueNat MTB-Rif’ in the National Tuberculosis Elimination Programme (at the time known as the Revised National Tuberculosis Control Programme).
• 2018: Launch of fully- automatic PCR device ‘Truelab Uno’ and approved by the Indian Council for Medical Research (ICMR).
• 2019: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time PCR test for hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
• 2019: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time duplex PCR test for human papillomavirus high risk types 16, 31 and 18, 45 from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
• 2019: Investment by India Business Excellence Fund III in the company.
• 2020: World Health Organisation endorsed TrueNat as the primary diagnostic test for MTB and MTB-RIF.
• 2020: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time PCR test for beta coronavirus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
• 2020: Received ‘License to manufacture for sale and distribution of medical device’ for chip based real time PCR test for HIV-1 virus from the Central Drugs Standard Control Organisation, Ministry of Health, Government of India.
• 2022: Investment by V Sciences Investments Pte. Ltd. in the company.
• 2023: Acquisition of Prognosys Medical Systems Private Limited to venture into radiology equipment.
• 2023: Acquisition of Prognosys Healthcare (India) Private Limited.
• 2024: Launched ‘Edge’, a scaleup partnership initiative between the company and Bigtec.
• 2024: Investment of 19.68% of the paid-up equity share capital of OptraScan, INC to diversify to digital pathology scanners.
• 2025: First Indian company to receive the Class C IVDR (EU 2017/746) Technical Documentation Assessment Certificate for Truenat CT/NG which has been issued by TUV SUD Product Service GmbH.
• 2025: Investment of an additional 40.32% of the paid-up equity share capital of OptraScan INC.
• 2025: Prognosys Medical Systems Private Limited received US FDA 510(k) clearance for PRORAD ATLAS ULTRAPORTABLE AND ULTRAPORTABLE PLUS.
• 2026: Prognosys Medical Systems Private Limited received EU Quality Management System certification under EU MDR 2017/745 for its PRORAD range of radiology systems.
• 2026: Truenat HR-HPV Plus meets International Agency for Research on Cancer (IARC) validation criteria in multicentre study.
• 2026: The company entered into a collaboration and license agreement with Equine Biotech Private Limited for development of veterinary diagnostic products, including assay design and validation.
• 2026: OptraScan, INC received US FDA 510(k) clearance (K260755) for its OptraSCAN System.